Previous Article | Next Article 
Molecular and Cellular Biology, November 2000, p. 8143-8156, Vol. 20, No. 21
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Loss of a Protein Phosphatase 2A Regulatory Subunit
(Cdc55p) Elicits Improper Regulation of Swe1p Degradation
Haifeng
Yang,
Wei
Jiang,
Matthew
Gentry, and
Richard L.
Hallberg*
Department of Biology, Syracuse University,
Syracuse, New York 13244
Received 20 March 2000/Returned for modification 12 May
2000/Accepted 2 August 2000
 |
ABSTRACT |
CDC55 encodes a Saccharomyces cerevisiae
protein phosphatase 2A (PP2A) regulatory subunit.
cdc55-null cells growing at low temperature exhibit a
failure of cytokinesis and produce abnormally elongated buds, but
cdc55-null cells producing the cyclin-dependent kinase
Cdc28-Y19F, which is unable to be inhibited by Y19 phosphorylation, show a loss of the abnormal morphology. Furthermore,
cdc55-null cells exhibit a hyperphosphorylation of Y19. For
these reasons, we have examined in wild-type and cdc55-null
cells the levels and activities of the kinase (Swe1p) and phosphatase
(Mih1p) that normally regulate the extent of Cdc28 Y19 phosphorylation.
We find that Mih1p levels are comparable in the two strains, and an
estimate of the in vivo and in vitro phosphatase activity of this
enzyme in the two cell types indicates no marked differences. By
contrast, while Swe1p levels are similar in unsynchronized and
S-phase-arrested wild-type and cdc55-null cells, Swe1
kinase is found at elevated levels in mitosis-arrested
cdc55-null cells. This excess Swe1p in
cdc55-null cells is the result of ectopic stabilization of
this protein during G2 and M, thereby accounting for the
accumulation of Swe1p in mitosis-arrested cells. We also present
evidence indicating that, in cdc55-null cells, misregulated PP2A phosphatase activity is the cause of both the ectopic
stabilization of Swe1p and the production of the morphologically
abnormal phenotype.
 |
INTRODUCTION |
Eukaryotic cell cycle progression
requires the sequential differential regulation of cyclin-dependent
protein kinases (CDKs). In general, CDK activity can be regulated at
four posttranslational levels (reviewed in reference
37): the binding of a positive regulator (a cyclin),
the binding of a negative regulator (a CDK inhibitor), activating
phosphorylation at threonine 169 (Saccharomyces cerevisiae)
or at homologous sites in other organisms (e.g., T161 in
Schizosaccharomyces pombe), or inhibiting phosphorylation at tyrosine 19 (S. cerevisiae) or at homologous sites (e.g.,
Y15 in S. pombe).
By regulating the state of phosphorylation of tyrosine 15 of the CDK
Cdc2p, organisms such as S. pombe, Xenopus
laevis, and humans can effectively coordinate the timing of the
entry into mitosis with the correct completion of DNA synthesis
(5, 20, 39, 53) or with an assessment of the integrity of
the genome (5, 20, 38). The phosphorylation of Y15 in
normally growing cells also has the effect of maintaining Cdc2 kinase
activity at low levels so as to prevent the ectopic initiation of
mitotic events (9). Wee1 kinase and its homologs
phosphorylate Y15; Cdc25 phosphatase and its homologs remove this
phosphate. In S. pombe, mutations in the genes encoding
Wee1p and Cdc25p can elicit severe mitotic defects (44, 45).
When DNA replication is blocked or DNA is damaged, a checkpoint signal
causes an enhancement of Wee1 function and an inhibition of Cdc25
activity, thereby causing cells to arrest at G2/M and
preventing premature entry into mitosis. In S. cerevisiae,
the phosphorylation (and dephosphorylation) of tyrosine 19 on its major
CDK, Cdc28p, is not required for mitotic timing, nor is it required for
DNA replication or DNA damage checkpoint-mediated cell cycle arrest
(1, 55). Rather, regulating Y19 phosphorylation of Cdc28 in
S. cerevisiae appears to be related to checkpoint mechanisms
associated with monitoring the morphological integrity of the cell, be
it the actin cytoskeleton (28, 47) or the septin ring of the
developing bud neck (3). When the actin cytoskeleton is
disrupted either by drug treatment or the effect of conditional
mutations, Swe1p, the S. cerevisiae Wee1p homolog, is
stabilized, thereby conferring a mitotic delay. When septin function is
compromised, Hsl1, Gin4, and Kcc4 kinases redundantly mediate a
Swe1-dependent delay of entry into mitosis. It is not known whether
these two pathways share components or not.
Protein phosphatase 2A (PP2A) is a major serine/threonine phosphatase
whose function has been implicated in a variety of cellular functions
including DNA replication, cell cycle progression, RNA transcription,
RNA splicing, and translation (60). With regard to its cell
cycle function, PP2A has been identified as a negative regulator of
entry into mitosis. For example, a factor purified from X. laevis egg extracts that prevents the activation of Cdc2 kinase
activity was shown to be a form of PP2A (25). It was also
reported that PP2A activity, as inferred from treatment with okadaic
acid, a relatively specific PP2A inhibitor, was required to maintain
high levels of Xe-Wee1p (the Xenopus Wee1p homolog) activity
during DNA replication in X. laevis egg extracts
(53). More recently, in this same system, it was shown that
okadaic acid increased the rate of degradation of Xe-Wee1p and
prematurely induced mitosis in the presence of a DNA replication
checkpoint; inactivating the Skp1-Cdc53/Cul1-F-box protein
(SCF)-ubiquitinating complex prevented this ectopic mitotic entry, most
likely through the stabilization of Xe-Wee1p (32). In
S. pombe, loss of one of the two PP2A catalytic subunits
causes a wee1-like phenotype and is synthetically lethal with certain
mutant alleles of wee1+. This same deletion
partially suppressed the growth defect of cdc25 mutants,
supporting the notion that PP2A acts as a positive regulator of Wee1
and/or as a negative regulator of Cdc25 (23). By contrast,
in S. cerevisiae, PP2A appears to be a positive regulator of
entry into mitosis. In a situation in which PP2A catalytic activity was
depleted from the cell, Clb2/Cdc28 kinase activity became severely
reduced and cells arrested as large budded 2N cells at G2/M
(28). This raises two questions: what role, if any, does
PP2A play in S. cerevisiae with regard to the regulation of
phosphorylation of Y19 of Cdc28p, and, if required for this regulation,
through what mechanisms does it achieve that control?
PP2A is thought to function primarily as a heterotrimeric complex
composed of a catalytic subunit (C) and two others (A and B) serving
regulatory functions (reviewed in references 34, 56, 58, and
60). The A subunit in S. cerevisiae is encoded by
TPD3 (57). It serves as a structural platform to
which one of the two B-regulatory subunits, Rts1p (46) or
Cdc55p (16), and one of the catalytic subunits, Pph21p or
Pph22p (40, 54), bind. The deletion of either
PPH21 or PPH22 elicits no mutant phenotype, but
the loss of Pph21p, Pph22p, and Pph3p (a protein sequence-related to
Pph21p and Pph22p) causes abnormal bud shape, abnormal actin
cytoskeleton, a G2/M delay, and a weakened cell wall
(14, 28). Deletion of either RTS1 or
CDC55 produces cells with completely different mutant
phenotypes. rts1-null cells are temperature sensitive for
growth at 37°C and are defective in their ability to respond to a
number of physiological stresses (13, 46, 47). By contrast,
cdc55-null cells grow slowly at low temperature and exhibit
an abnormal budding morphology (16). They are also defective
in establishing a spindle damage checkpoint, losing viability rapidly
when exposed to normally nontoxic doses of nocodazole or benomyl
(35, 59). rts1-null and cdc55-null
cells share no apparent overlap of phenotypic deficiencies. The
double-null rts1
cdc55
mutant exhibits a combination
of the two single-null phenotypes (46).
At low temperatures, cdc55-null cells exhibit an elongation
of buds and a failure of cytokinesis and cell separation
(16). The abnormal morphology is abolished in these cells if
they also express a CDC28 gene in which Y19 is changed to
F19, thereby rendering the inhibitory phosphorylation site on Cdc28p
nonphosphorylatable (59). When measured directly, the
phosphorylation level on tyrosine 19 of Cdc28 in cdc55-null
cells is higher in cycling and nocodazole-arrested cells than in
similarly treated wild-type cells (35). These results
suggested a probable role for PP2A in regulating Cdc28 tyrosine phosphorylation.
We have addressed the question of what causes the elevated
phosphorylation levels of Cdc28 Y19 in cdc55-null cells.
More specifically, we wanted to know if PP2A activity is required for
the regulation of either Swe1 kinase activity or Mih1 (the S. cerevisiae Cdc25 homolog) phosphatase activity and, if so, how
losing Cdc55p disrupts this regulation. What we have found is that the
loss of Cdc55 affects the normal regulation of Swe1p turnover, causing
cells to accumulate abnormally high levels of this protein at mitosis. Furthermore, this ectopic accumulation and resultant excess Swe1 kinase
activity are likely caused by a gain of a formerly repressed PP2A
catalytic function. Our data also show that, as in other eukaryotes,
PP2A function is required in S. cerevisiae for regulating the inhibitory phosphorylation of its CDK.
 |
MATERIALS AND METHODS |
Plasmids and strains.
All strains used were derivatives of
W303. The wild-type and cdc55-null
(cdc55
::TRP1) strains have been previously
described (46). A cdc55-null swe1-null
strain was generated by transformation of the cdc55-null
strain by one-step gene disruption (42) using a
BamHI-HindIII-digested
swe1
::LEU2 knockout construct (6). W303 strains null for PPH21 and PPH22 (DEY132-1C
[pph21
::HIS3] and DEY10-2B
[pph22
::URA3]) were obtained from D. Evans.
Strains null for CDC55 and one or both of the genes encoding
the PP2A catalytic subunits were generated by crosses, tetrad
dissection, and phenotypic screening to identify the appropriate
genotypic segregants. W303 strains carrying chromosomally integrated
copies of CDC28:HA (ADR508) or Y19F-CDC28:HA
(ADR640) were obtained from A. Murray. These genes were introduced into
the appropriate deletion strains by standard crosses. A W303 strain
(PS701) containing a MIH1 knockout
(mih1
::LEU2) was obtained from P. Sorger.
This strain and the cdc55-null strain were individually
crossed to ADR508 to obtain mih1
CDC28:HA and
cdc55
CDC28:HA segregants, respectively.
W303-derived strain 1522 expressing an integrated PDS1:HA
gene was obtained from D. Koshland, who also supplied us with a plasmid
(pOC42) carrying a GAL1-driven PDS1:HA gene. The
chromosomal PDS1:HA was introduced into our laboratory
CDC55 and cdc55
strains using standard
crosses. We obtained strain PY1212 carrying a cdc23-1 allele
from D. Pellman. This gene was also introduced into the appropriate
strains by standard genetic crosses.
To create strains expressing an HA-tagged form of CLN2, we
obtained the CLN2-HA-LEU2-tagging plasmid MT104 from M. Tyers. This plasmid was digested with PvuII, thereby
liberating an insert that will integrate at the CLN2 locus.
Using this digest, transformations to obtain single-step gene
replacements were carried out using wild-type and cdc55-null
strains; Leu2+ transformants were isolated, and Western
blot analyses permitted us to identify strains producing HA-tagged
forms of Cln2p.
To create strains expressing a MYC-tagged MIH1 gene, we
obtained a plasmid from D. Lew carrying the final 683 bases of the MIH1 ORF followed by 12 MYC sequences, a stop codon, and 471 bases of the 3' N-terminal repeat. Partial NdeI digests of
this pRS306-based plasmid were used to transform either wild-type or
cdc55-null cells, selecting for the URA3 marker
of the plasmid. Proper integration produces cells with a full-length
MIH1:MYC12 gene and an MIH1 gene
truncated at its 5' end. The correct expression of the MYC-tagged MIH1 gene was confirmed by comparing, by Western analysis,
the transformed strains with a positive control (strain JMY1319:
mat
MIH1:MYC12
[c-term]:URA3:mih1-5'
) supplied by D. Lew.
The SWE1-myc-tagging plasmid construct DLB940
(31) was also obtained from D. Lew. A derivative plasmid of
DLB940 (based on pRS306 [51]) was created by removing
an XbaI/ClaI fragment, filling in bases to
generate blunt ends, and then self-ligating the resultant plasmid. This
derivative, from which the GAL1 promoter and N-terminal
two-thirds of SWE1 were removed, was cut at a
KpnI site near the C terminus of SWE1 and used to
transform wild-type and cdc55
strains, selecting for
uracil prototrophy. This process produced cells containing a single
copy of SWE1:MYC12 and an adjacent truncated,
promoterless SWE1. Transformants were grown on rich medium
for 3 days and then plated on 5'-fluoroorotic acid to select for cells
that had lost the URA3 gene. Western analyses were carried out to confirm that the cells produced a myc-tagged Swe1p. To generate
strains that were cdc55
pph21
pph22
SWE1-myc,
cdc55
::TRP1 SWE1-myc cells were mated with
pph21
::HIS3 pph22
::URA3 cells, tetrads were dissected, and the triple knockout expressing an epitope-tagged SWE1 was identified by the presence of three
selective markers and, as shown by a Western analysis, the presence of
a myc-tagged Swe1p.
Wild-type and cdc55
strains with
GAL1:SWE1:MYC12 as the only functional
chromosomal copy of SWE1 were generated as follows. Wild-type and cdc55-null cells were transformed with the
BamHI-HindIII-digested swe1
::LEU2 construct as described above. After
confirming that the SWE1 gene was disrupted, cells were
transformed with a StuI-digested DLB940 (the
pRS306-GAL1-SWE1-myc-tagging construct [see above]) which
would direct integration of the plasmid into the URA3 locus. This then generated a strain with
GAL1:SWE1:MYC12 as the only gene expressing a
functional copy of SWE1. This strain was finally crossed to
the cdc55-null strain, diploids were sporulated, asci were
dissected, and the segregants were screened in order to identify cells
that were cdc55
::TRP1 swe1
::LEU2
and had GAL1:SWE1:MYC12 at the URA3 locus.
To create cells in which chromatid separation could be monitored, we
obtained W303 strains from J. Bachant (JBY583 and JBY584), each of
which contained integrated copies of TetR-GFP-LEU2 and TetO-URA3 (33) but which differed only in mating
type. Crosses were made with our standard CDC55 and
cdc55
strains, and the appropriate segregants were
identified for subsequent chromatid analysis.
Cell growth conditions.
Standard yeast protocols and media
were used (41). To arrest cell growth, hydroxyurea was added
to culture media to a final concentration of 0.2 M; nocodazole was
added to a final concentration of 20 µg/ml. In all cases, cells were
microscopically examined (either by differential interference-contrast
[DIC] for cell morphology or 4',6'-diamidino-2-phenylindole [DAPI]
staining/fluorescence for nuclear morphology) throughout all
experiments to ensure that cell cycle arrest had occurred and that such
arrest was maintained. The exact conditions used for specific
experiments are given in the appropriate figure legends.
DAPI staining and microscopy.
Staining cells with DAPI to
determine the state of arrest of cells was carried out by the method of
Honigberg and Esposito (17). Cells growing in liquid
cultures were ethanol fixed directly in growth medium. Cells growing on
solid medium were scraped off, washed once in water, and then fixed.
For quantitative measurements, 200 to 300 cells were counted for each
time point. Visualization of cells by DIC microscopy was carried out on
a Nikon Eclipse TE300 microscope. Visualization of cells using DAPI or
green fluorescent protein (GFP) fluorescence was done on an Olympus
BX60 microscope. For quantitation purposes, images were captured using
an Optronics cooled charge-coupled device camera.
Northern analyses.
Cells to be analyzed were centrifuged and
stored as frozen pellets at
80°C. Total RNAs were prepared using a
hot-phenol extraction method (24). RNAs were denatured,
separated on 1% agarose gels, transferred to filters, and hybridized
with a radioactive probe as previously described (47). An
Swe1 mRNA probe was generated by labeling a 0.6-kb
HindIII-XbaI SWE1 ORF fragment
with [
-32P]ATP, using a random labeling kit from Life Technologies.
Protein isolation, electrophoresis, and Western analysis.
The direct extraction of total proteins by solubilizing cells in 1.8 M
NaOH-5% beta-mercaptoethanol (
-ME), the separation of proteins by
sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE),
and procedures used for Western analysis have been previously described
(46, 47). The antibody against phospho-Tyr15-CDC2 (New
England Biolabs) was used following the instructions of the supplier.
The mouse monoclonal antibodies 12CA5 and 9E10 were used to detect HA
epitope-tagged proteins and MYC epitope-tagged proteins, respectively.
Cdc28p and Pho85p were detected using the mouse PSTAIR monoclonal
antibody (Sigma). The final visualization of proteins was done using
alkaline phosphatase-conjugated second antibodies as previously
described (47) or by using horseradish peroxidase
(HRP)-conjugated second antibodies and enhanced chemiluminescence (ECL; Amersham).
To phosphatase treat myc-tagged Mih1p, cells were dissolved using
NaOH-
-ME (46), and the solubilized proteins were
trichloroacetic acid precipitated. After resolubilization of the
precipitated proteins (46), 9E10 antibody and
agarose-protein A beads were added to immunoprecipitate the Mih1-myc
proteins. The protein A beads containing the adsorbed proteins were
washed into an appropriate buffer and treated with 200 U of calf
intestinal alkaline phosphatase (Promega). Following the phosphatase
treatment, proteins were released from the protein A beads for SDS-PAGE
separation and Western analysis.
Mih1p in vitro phosphatase activity assay.
Growing
CDC55 and cdc55
strains expressing an
MIH1-MYC gene were arrested in nocodazole for 3 h. As
negative controls, CDC55 and cdc55
cells
expressing a normal MIH1 gene were treated in the same way.
Such cells were harvested and frozen at
80°C. Subsequently thawed
cells were broken by glass beads at 4°C in an immunoprecipitation (IP) buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 5 mM EGTA, 0.1%
NP-40, 2.7 mM KCl) supplemented with a protease inhibitor cocktail
(Boehringer Mannheim) and 1 mM phenylmethylsulfonate fluoride (PMSF).
Following cell breakage, the lysates of the four samples were
centrifuged at high speed at 4°C for 5 min (all subsequent steps were
carried out at 4°C unless specified otherwise). The lysates were
transferred to clean centrifuge tubes, and to each was added 20 µl of
a 1:1 slurry of protein A beads equilibrated with IP buffer. The tubes
were gently agitated for 20 min, after which they were centrifuged at
high speed for 5 min. Each of the cleared lysates (ca. 0.5 ml) was
removed and transferred to a clean centrifuge tube, and 4 µl of 9E10
anti-myc mouse monoclonal antibody (1 mg/ml; Zymed) was added. These
tubes were then gently agitated for 40 min, after which 100 µl of a
1:1 protein A bead-IP buffer slurry was added and agitation was
continued for an additional 45 min. The protein A beads were collected
by centrifugation at 4,000 × g for 5 s. The supernate
was then removed, and the beads were washed three times with 1 ml of IP
solution and then twice with 1 ml of phosphatase assay buffer (50 mM
Tris-Cl [pH 8.0], 50 mM NaCl, 1 mM EDTA). Following the second wash,
one-tenth of the beads were collected by centrifugation and boiled in
20 µl of 2× SDS-PAGE loading buffer. These samples were used to
detect the amount and modification of Mih1p in each immunoprecipitate before the phosphatase assay. The myc-tagged Mih1p from the
CDC55- and cdc55-null cells adsorbed to the
protein A beads served as the source of phosphatase to be assayed in vitro.
To prepare a substrate for Mih1 phosphatase activity, growing
mih1-null cells expressing CDC28:HA were treated
with nocodazole for 3 h and collected. Such a treatment maximizes
the cellular level of phospho-Y19-Cdc28p, the substrate used to monitor
the Mih1 phosphatase activity. These cells were then broken with glass beads in IP buffer supplemented as above with a protease inhibitor cocktail and PMSF. The resulting lysate was centrifuged twice for 5 min
at 20,000 × g. The cleared lysate was then gently agitated at 23°C for 10 min to bring it up to assay temperature, after which
it was divided into four equal parts (about 250 µl each), each then
being added to one of the above four protein A-agarose bead
immunoprecipitates. The mixtures were vigorously agitated at 23°C,
and at 0, 15, 30, 45, and 60 min of incubation, the beads were briefly
pelleted, and 14 µl of the lysates was taken from each reaction and
boiled with 16 µl of 2× SDS-PAGE sample loading buffer. Also, at the
end of the incubation, an aliquot containing one-sixth of the initial
amount of washed protein A beads was also assayed to check Mih1p
abundance and modification. The visualization of either
phospho-Y19-Cdc28p, Cdc28-HA, or Mih1-myc was carried out as described above.
To quantify signals on Western blots, films or stained gels were
scanned into a computer using Adobe Photoshop 4.0 LE. The images were
then analyzed using either NIH Image 1.62 software (Fig. 4a, 6, and 7b)
or Kodak 3.0.2 software (Fig. 3c and 3d).
 |
RESULTS |
cdc55-null cells remain arrested in mitosis when
treated with nocodazole.
It was shown (35) that
cdc55-null cells have an increased level of phosphorylation
of Cdc28p tyrosine 19 (Y19) when compared with wild-type controls. The
extent of phosphorylation at Y19 is controlled by two counteracting
enzymes: Swe1p (a kinase) and Mih1p (a phosphatase). Thus, assuming
that no other previously unrecognized enzymes are involved, either
higher Swe1 kinase activity or lower Mih1 phosphatase activity in
cdc55-null cells accounts for the increased Cdc28p
Y19-phosphorylation level. Our goal was to establish which alternative
applied for cdc55-null cells.
The extent of excess Y19 phosphorylation in cdc55-null cells
relative to controls is far more pronounced when cells are treated with
nocodazole (35; H. Yang, unpublished results), and
we therefore wished to make our measurements in such drug-treated
cells. Nocodazole causes metaphase arrest by depolymerizing
microtubules (10), thereby triggering the spindle damage
checkpoint (27). It was reported that cdc55-null
cells have a defective spindle damage checkpoint pathway, with cells
quickly losing viability in the presence of nocodazole (35,
59). Such cells initiate sister chromatid separation in the
presence of spindle damage and thus, by definition, fail to arrest at
metaphase. But unlike other spindle damage checkpoint mutants,
nocodazole-arrested cdc55-null cells do not degrade mitotic
cyclins Clb2p and Clb3p (35). It was therefore proposed that
cdc55-null cells have a normal initial response to spindle
damage but are unable to maintain the mitotic arrest (43).
If true, we would be unable to reliably compare nocodazole-treated
cdc55
and wild-type cells, as they would not remain
arrested at the same cell cycle stage. Therefore, we asked two
questions: (i) do nocodazole-treated cdc55-null cells have a
normal initial spindle damage checkpoint response, and (ii) do
cdc55-null cells enter the next cell cycle during prolonged nocodazole treatment?
To address the first question, we compared the protein stability of
Pds1p in wild-type and cdc55
cells. Pds1p is an anaphase inhibitor whose degradation is required for sister chromatid separation (8), and it is one of the major targets of the spindle
damage checkpoint pathway (62). When spindle damage is
sensed, the Mad1p-Mad2p-Mad3p complex prevents the rapid Cdc20
anaphase-promoting complex (APC)-mediated degradation or Pds1p. The
relatively stabilized Pds1p then prevents sister chromatid separation
(18). If the spindle damage checkpoint were not triggered by
nocodazole in cdc55-null cells, Pds1p would be expected to
be much more unstable in these cells than in wild-type controls and
would presumably be degraded in the presence of nocodazole. To test
these ideas, we transformed wild-type and cdc55-null cells
with a plasmid carrying an HA-tagged PDS1 driven by the
GAL1 promoter. Both strains were grown in raffinose medium
and treated with nocodazole for 3 h. Galactose was added to
transiently induce the production of Pds1p, and the cells were then
washed into medium containing dextrose (to repress the GAL1
promoter) and nocodazole (to maintain the arrest). Samples were
withdrawn at different time points after transcription repression,
total cell proteins were extracted, and a Western blot analysis was
performed to detect Pds1-HA. We found (Fig.
1A) that
Pds1p was as stable in nocodazole-treated cdc55-null cells
as in wild-type cells.

View larger version (55K):
[in this window]
[in a new window]
|
FIG. 1.
Nocodazole-treated cdc55 cells remain
arrested in mitosis. To determine whether nocodazole-treated
cdc55-null cells maintain a mitotic arrest, we examined the
metabolism of Pds1p and Cln2p in these cells and compared it to that
seen in wild-type controls. To examine Pds1p initially, isogenic
wild-type (CDC55) and cdc55 strains, each
transformed with a plasmid carrying an HA-tagged PDS1 gene
behind a GAL1 promoter (see Materials and Methods), were
grown in raffinose medium to early log phase. Nocodazole was then added
to the culture medium to 20 µg/ml to arrest cell growth, and 3 h
later, galactose was added to induce the accumulation of HA-tagged
Pds1p. After 2 h, cells were collected by centrifugation, washed
once, and then, to repress further PDS1 transcription,
resuspended in dextrose medium containing nocodazole to maintain
mitotic arrest. Cell samples were collected immediately and at 0.5-h
intervals for 2 h after PDS1 turnoff. Total cell
proteins (see Materials and Methods) were separated by SDS-PAGE,
transferred to nitrocellulose filters, and immunoblotted using 12CA5
anti-HA antibody to detect Pds1p (A). The lower half of the gel not
used for the protein transfer was stained with Coomassie blue to show
the relative protein loading in each lane. Endogenous Pds1p levels were
determined in CDC55 and cdc55-null strains at
various times during an extended exposure to nocodazole or after a
release from a 3-h nocodazole arrest (B). Wild-type and
cdc55-null cells, each expressing an HA-tagged
PDS1 gene (see Materials and Methods), were grown to early
log phase in YPD medium. Nocodazole was added to both cultures, and
aliquots of cells were collected at 0, 1, 2, and 3 h. After 3 h in nocodazole, the remaining wild-type and cdc55
cultures were split in half. One-half of the cells remained in YPD
containing nocodazole. The other cells were collected, washed, and then
resuspended in fresh YPD containing no nocodazole to allow cells to
enter the cell cycle. Aliquots of cells were collected 20, 40, 60, 80, and 100 min later. Western analyses were carried out to measure Pds1p
levels (upper panels), and those portions of the gels not used for
protein transfer were stained to show the relative loading in each
lane. Lanes 1 through 4, cells in nocodazole at 0, 1, 2, and 3 h;
lanes 5 through 9, cells at 20, 40, 60, 80, or 100 min after nocodazole
release; lanes 10 through 14, cells in nocodazole at 20, 40, 60, 80, or
100 min after the initial 3-h drug incubation. Cln2p levels were determined in CDC55 and cdc55-null
strains at various times during an extended exposure to nocodazole or
after release from a 3-h nocodazole arrest (C). Wild-type and
cdc55-null cells, each expressing an HA-tagged
CLN2 gene (see Materials and Methods), were grown to early
log phase in YPD medium. Nocodazole was added to both cultures, and
aliquots of cells were collected at 0, 1, 2, and 3 h. After 3 h in nocodazole, the remaining wild-type and cdc55
cultures were split in half. One-half of the cells remained in YPD
containing nocodazole. The other cells were collected, washed, and then
resuspended in fresh YPD containing no nocodazole to allow cells to
reenter the cell cycle. Aliquots of cells were collected 1, 2, and
3 h later. Western blot analyses were carried out to measure Cln2p
levels (upper panels), and that portion of the gel not used for protein
transfer was stained to show the relative loading in each lane. Lanes 1 through 7, cells in nocodazole at 0, 1, 2, 3, 4, 5, and 6 h; lanes
8 through 11, cells at 0, 1, 2, and 3 h after nocodazole release
at 3 h. Note: lanes 4 and 8 contain the same protein samples.
|
|
This similarity in Pds1p stability in the two strains predicted that
the endogenous level of this protein should fluctuate in a similar
fashion in strains both treated with nocodazole and subsequently
released from cell cycle arrest. This proved to be the case when we
measured Pds1p levels in cells arrested in nocodazole for 3 h and
then washed into fresh drug-free medium (Fig. 1B). In both wild-type
and cdc55-null cells, Pds1p levels remained high during
nocodazole treatment (Fig. 1B, lanes 1 through 4); they decreased and
subsequently increased following removal of the drug, which led to an
exit from mitosis (lanes 5 through 9); and they remained relatively
high in cells which were not removed from nocodazole (lanes 10 through
14). Thus, the metabolism of Pds1p does not appear to be abnormal in
cdc55
cells, indicating that these cells have a normal
mitotic checkpoint response and are able to maintain this response
during prolonged nocodazole treatment.
It was still possible that, while nocodazole-treated
cdc55-null cells respond correctly to spindle damage, they
were unable to maintain an arrest and therefore incorrectly entered
G1 of the next cell cycle without degrading Pds1p. A clear
marker for such an event would be the appearance of Cln2p, one of the
G1 cyclins that, while absent in mitotic cells, rapidly
accumulates in G1 following completion of mitosis
(61). Accordingly, wild-type and cdc55
strains
carrying chromosomally integrated CLN2:HA genes were grown
in yeast extract-peptone-dextrose (YPD) to early log phase and then
treated with nocodazole. Samples were withdrawn for Western analyses at
1-h intervals for 6 h following drug addition. In addition, after
3 h in nocodazole, half of the cells in each culture were washed
in fresh YPD carrying no drug (in order to monitor their ability to
recover) while the other half remained in YPD-nocodazole. Cells removed
from the drug were examined microscopically at 1-h intervals to assess
the morphological status of these cells as well as being analyzed for
Cln2p levels. As seen in Fig. 1C, Cln2p levels quickly declined in both
wild-type and cdc55-null cells following nocodazole
treatment (Fig. 1C, lanes 1 through 7), reaching a minimum at about
2 h, followed by a slight recovery after 3 to 4 h. While the
extent of decline in Cln2p was not quite as severe in
cdc55-null cells, in neither case, even after 6 h in
nocodazole, did the recovery show Cln2p to approach pre-drug treatment
levels (compare Fig. 1C, lanes 1 and 7). As most (>80%) of both cell
types remained large budded with a single nucleus (data not shown),
what this slight recovery in Cln2p levels represents is not known. The
slightly higher Cln2p levels in nocodazole-treated cdc55
cells are likely a result of a reported low mitotic Cdc28 kinase
activity (35), since this activity is required to repress CLN2 transcription (2).
For both wild-type and cdc55-null strains, cells released
from a 3-h nocodazole arrest showed a dramatic increase in Cln2p levels
within 1 h (Fig. 1C, lane 9), in both cases exceeding the levels
detected in the original asynchronous culture. At 1 h, essentially
all wild-type cells had small buds while about 30 to 40% of the
cdc55-null cells showed a similar morphology (data not
shown). This is consistent with the fact that wild-type cells show a
much more robust increase in Cln2p levels. Presumably, the reduced
response on the part of cdc55-null cells reflects the
ultimately lethal effects of nocodazole treatment on these cells.
To make sure that cdc55
cells behaved in our experiments
as has been previously reported (35), we monitored sister
chromatid separation in nocodazole-treated cells. To do that, a gene
expressing a tetracycline repressor (TetR)-GFP fusion construct and
genes containing 112 tandem tetracycline operator (TetO2)
sequences (33) were introduced into wild-type and
cdc55
cells to help visualize sister chromatids (see
Materials and Methods). Both strains were synchronized by hydroxyurea
(HU) treatment and then washed into fresh medium containing nocodazole.
The percentage of cells with separated sister chromatids was scored
following the start of nocodazole treatment. Our findings were the same as those earlier reported (35), with cdc55
cells showing significant premature sister chromatid separation and
with wild-type controls showing little or none (data not shown). Thus,
our cdc55
cells treated with nocodazole separated their
sister chromatids but did not exit mitosis.
In summary, mitotic cyclins are not degraded in nocodazole-arrested
cdc55-null cells (35), and our results showed
that Pds1p and Cln2p metabolism was similar in cdc55-null
and wild-type controls. In addition, microscopic analysis of
nocodazole-treated cdc55-null cells showed that even after
6 h in drug, the vast majority of cells remained large budded with
a single nucleus at the mother-bud neck (data not shown). Furthermore,
these cells never rebudded. As premature sister chromatid separation in
cdc55-null cells occurs relatively slowly
(35; H. Yang, W. Jiang, M. Gentry, and R. L. Hallberg, unpublished data), we concluded, in disagreement with
Minshull et al. (35), that cdc55
cells treated
with nocodazole did arrest at a mitotic stage similar to that of
nocodazole-treated wild-type cells, and thus, we could legitimately
compare Swe1p and Mih1p activities in these cells.
Mih1 phosphatase activity is similar in cdc55-null and
wild-type cells.
As the hyperphosphorylation of tyrosine 19 of
Cdc28p was positively correlated with (and appeared to be directly
responsible for) the morphological abnormalities manifested in
cdc55-null cells (35, 59), we investigated the
possible causes of this state of excess phosphorylation. Swe1 kinase
and Mih1 phosphatase are the only reported S. cerevisiae
enzymes that either add or remove phosphates from the Y19 residue of
Cdc28p. Thus, either higher Swe1 kinase activity or lower Mih1
phosphatase activity in cdc55-null cells must account for
the increased phosphorylation state of Cdc28p.
As it has been reported (31) that protein levels of Mih1
phosphatase normally remain unchanged during the cell cycle, the simplest way that Mih1 phosphatase activity could be decreased in
cdc55-null cells would be if its cellular amount were to
decrease at some time during the cell cycle. To test this, we tagged
the MIH1 gene with a MYC epitope and measured the levels of
MYC-tagged Mih1p in wild-type and cdc55-null cells either
growing exponentially or arrested at different points in the cell cycle
(Fig. 2a). In no cases were Mih1p levels
obviously decreased in cdc55-null cells relative to
controls. Unexpectedly, we did find that the electrophoretic mobility
of Mih1p was different at different points in the cell cycle and, more
importantly, these variations were different in cdc55-null
cells. Alkaline phosphatase treatment of immunoprecipitated Mih1p
showed (Fig. 2b) that the differences in electrophoretic mobility were
predominantly the effects of differential phosphorylation of this
protein.

View larger version (69K):
[in this window]
[in a new window]
|
FIG. 2.
Mih1p levels in wild-type and cdc55-null
cells are similar. To determine Mih1p levels, wild-type (i.e.,
CDC55) and cdc55-null strains expressing an
MIH1 gene tagged with 12 copies of the MYC epitope were
constructed (see Materials and Methods). Such cells growing in YPD
medium at 30°C were collected as unsynchronized cycling cells (lanes
1 and 2), cells arrested in S phase with 0.2 M HU for 3 h (lanes 3 and 4), or cells arrested in mitosis with 20 µg of nocodazole (noc)
per ml for 3 h (lanes 5 and 6). Total cell proteins were extracted
as described above, separated by SDS-PAGE, transferred to filters, and
immunodecorated using the 9E10 anti-MYC antibody to detect Mih1p (a).
The lower half of the gel not used for the protein transfer was stained
with Coomassie blue to show the relative protein loading. To determine
whether the heterogeneity of Mih1p gel mobility seen in (a) was due to
differential phosphorylation of Mih1p, proteins were extracted from
HU-arrested wild-type and cdc55 cells, immunoadsorbed to
protein A beads, and treated with alkaline phosphatase (see Materials
and Methods). Proteins released from the protein A beads were subjected
to a Western blot analysis (b) as above. ( p), untreated controls;
(+p), alkaline phosphatase treated.
|
|
Given the previous results, should there be a decreased Mih1
phosphatase activity in cdc55-null cells, it would have to
occur by virtue of a decrease in enzyme-specific activity. As protein phosphorylation can have either positive or negative effects on the
activities of both kinases and phosphatases, the obvious differences seen in the states of Mih1p phosphorylation in cdc55-null
relative to control cells make this an attractive candidate for
producing abnormal Mih1 phosphatase activity in these cells. To test
this, we measured the in vivo Mih1 phosphatase activity in wild-type and cdc55-null cells. This was possible for the following
reasons. When wild-type cells progress from S phase through
G2 to M phase, Mih1p levels remain constant (31)
but Swe1p levels greatly decline (31), and the extent of
tyrosine 19 phosphorylation on Cdc28p decreases as a result of the
activity of Mih1 phosphatase. Earlier studies (35) in which
CDC28 Y19 phosphorylation was determined relied on
immunoprecipitation of Cdc28p followed by subsequent assay of the
immunoprecipitated protein for the presence of tyrosine phosphorylation
using an antiphosphotyrosine antibody. We found that the
anti-phospho-Tyr15-CDC2 antibody (New England Biolabs) cross-reacted
with phospho-Tyr19-Cdc28 of S. cerevisiae in a total cell
protein extract (prepared by dissolving cells directly in 1.8 M NaOH)
with essentially no background (cells expressing only the
gene CDC28Y19F show no immunoreactive
proteins in the molecular-weight range of Cdc28p) (Fig.
3A). Thus, by using strains expressing a
chromosomally integrated, HA-tagged CDC28 gene, we could
directly measure in any particular cell type the levels of Cdc28p and
the extent of Y19 phosphorylation of Cdc28p by a simple Western blot
analysis of total cell proteins. Accordingly, wild-type,
mih1-null, and cdc55-null cells in
early-log-phase growth were arrested in S phase by treatment with HU
for 3 h. Such cells should contain highly phosphorylated Cdc28p
(35) (Fig. 3B). The arrested cells were then washed and
split into two portions. One was resuspended in YPD medium without
drug. The cell cycle progression of these cells was monitored by
determining the percentages of telophase cells at various times after
resuspension. This showed (Fig. 3B, upper panels) that each strain
could recover from HU arrest and progress to telophase and into the
next G1 within 2 h. The other portion of cells was
resuspended in YPD medium containing nocodazole. These cells would have
recovered from the S-phase arrest but would now be secondarily arrested
at the subsequent mitosis, a time at which Swe1p should have
significantly decreased (31), thereby substantially reducing
any further Cdc28p phosphorylation. We measured the state of Cdc28 Y19
phosphorylation beginning at the S-phase arrest and at various times
following the S-phase release. We found (Fig. 3B, middle panel) that
the rates of initial loss of Cdc28 Y19 phosphorylation in wild-type and
cdc55-null cells were similar. However, the net extent of
phosphate removal was more complete in wild-type than in
cdc55-null cells. (We show later that this less complete
dephosphorylation is most likely due to excess Swe1 kinase activity in
mitosis-arrested cdc55-null cells.) By contrast, and as a
control, mih1
cells treated in a similar fashion showed
no decrease in Y19 phosphorylation during the course of the experiment,
confirming that Mih1 is the major, if not only, phosphatase that
dephosphorylates Y19 on Cdc28p (Fig. 3B). From these results we
concluded that Mih1 phosphatase activity is not qualitatively different
in wild-type and cdc55-null cells.

View larger version (48K):
[in this window]
[in a new window]
|
FIG. 3.
Measuring Mih1 phosphatase activity in wild-type and
cdc55-null cells. To test the ability of the
anti-phospho-Tyr15-Cdc2 antibody to detect S. cerevisiae
phospho-Tyr19-Cdc28, total proteins were isolated from growing,
unsynchronized cells expressing either an integrated HA-tagged Cdc28 or
an integrated Cdc28-HA in which tyrosine 19 was converted to a
phenylalanine (Y19F-Cdc28HA). Western blot analyses (A) were carried
out as in Fig. 2, first using anti-phospho-Tyr15-Cdc2 antibody (upper
panel) and, after washing the filter, using anti-HA antibody 12CA5
(lower panel). To compare the in vivo phosphatase activities of Mih1p
in wild-type, cdc55 , and mih1 strains (all
carrying integrated CDC28:HA genes), cells growing in YPD at
30°C were arrested with HU for 3 h. Cells were then collected by
centrifugation, washed, and treated in one of two ways. One-fifth of
the cells were resuspended in fresh YPD without HU. At various times
thereafter, aliquots of cells were fixed and stained with DAPI. By
microscopic examination, the percentages of large-budded cells with two
separated nuclei (telophase cells) in each population were determined
(B, upper panels). These samples were used to monitor the recovery of
cells from S-phase arrest and their subsequent entry into and passage
through telophase. The other four-fifths of the cells were resuspended
in YPD plus nocodazole so that the cells released from S phase arrest
would arrest again at the next metaphase. Aliquots of cells were
withdrawn at the time of S-phase release (t = 0) and at
various times thereafter (60, 90, 120, 150, and 180 min). At the end of
the experiment, cells were stained with DAPI to make certain they were
still arrested at metaphase as large-budded cells with a single
nucleus. Total cell protein extracts were prepared, and a Western blot
analysis was performed using the anti-phospho-Tyr15-Cdc2 antibody (B,
middle panels). Subsequently, the filter was washed and reprobed with
anti-PSTAIR monoclonal antibody to reveal the amount of Cdc28-HA
protein in each lane (B, lower panels). To compare the in vitro Mih1
phosphatase activity of wild-type and cdc55 cells
arrested in mitosis, Mih1p was immunoadsorbed to protein A beads from
lysates of cells (either cdc55 or CDC55)
expressing a MYC-tagged form of Mih1p (see Materials and Methods). As
negative controls, similar immunoadsorptions were carried out on
CDC55 and cdc55 strains expressing a normal
(i.e., nontagged) MIH1 gene. The protein A beads were added
to a soluble protein extract prepared from an
mih1 CDC28:HA strain that had been treated with nocodazole
for 3 h (see Materials and Methods for details). The
phospho-Y19-Cdc28p in such extracts served as the substrate for the
protein A-associated Mih1 phosphatase activity. Following protein A
bead addition, the extracts were incubated with agitation at 23°C,
and samples were withdrawn at 15-min intervals and, as above, analyzed
for phospho-Y19-Cdc28 levels and Cdc28p levels (C). The resulting
Western blots were quantitated, and the data for phospho-Y19-Cdc28 were
plotted (D). To test the effects of the enzyme assay incubation on the
quantity and quality of Mih1p recovered, aliquots of the protein A
beads containing Mih1-myc from CDC55 (wt) and
cdc55 ( c) strains were collected before (one-tenth of
the total) and after (one-sixth of the original total) the enzyme assay
incubation. The released Mih1p was then subjected to a Western blot
analysis (E).
|
|
To confirm the above results, we measured the in vitro Mih1p
phosphatase activity of the two cell types in the following way. Mih1p
in extracts made from nocodazole-arrested wild-type and cdc55-null cells, each expressing MIH1:MYC, was
immunoadsorbed onto protein A-agarose beads using anti-MYC antibody.
(As negative controls, anti-MYC and protein A beads were added to
extracts of both cell types not expressing MYC-tagged MIH1
genes.) Then cell lysates were made from an mih1
strain
that had also been nocodazole treated. As Mih1p phosphatase activity is
absent from such a strain, the phosphorylation of Cdc28p Y19 remains
maximal, and we found that the phosphorylated form of Cdc28p was stable in cell extracts for up to 3 h. Using such an extract as a source of substrate for the protein A-bound Mih1 phosphatases from wild-type and cdc55-null cells, we added the protein-bound beads to
the cell extract and determined the kinetics of Y19 phosphate removal from Cdc28p. As seen in Fig. 3C, no apparent loss in level of Y19
phosphorylation was observed in the controls (i.e., when the source of
Mih1p came from cells not expressing a MYC-tagged MIH1 gene), while in both cases in which Mih1-MYC was adsorbed to the beads,
the extent of Y19 phosphorylation decreased. When this decline was
quantitated (Fig. 3D), the rates of dephosphorylation were essentially
the same whether the source of Mih1p was wild-type or
cdc55-null cells. This was consistent with our in vivo findings.
As we had found that the state of phosphorylation of Mih1p was not the
same in nocodazole-arrested wild-type and cdc55-null cells
and to be sure that comparable amounts of Mih1p were assayed, we
examined the relative amounts and the states of phosphorylation of the
bead-bound Mih1p at the beginning and at the end of the incubation. As
seen in Fig. 3E, the electrophoretic differences in Mih1p, reflecting
the relative extents of phosphorylation, from the two cell types were
maintained throughout the course of the assay. Also, the levels of the
two proteins remained comparable as well (the fractions of the
immunoprecipitates analyzed before and after were not the same; see
figure legend). Thus, in neither our in vivo nor our in vitro assays of
Mih1p phosphatase activity does the state of Mih1p phosphorylation
detectably alter this activity. It remains to be determined what the
physiological and biochemical significance of the altered Mih1p
phosphorylation state in cdc55-null cells might be.
The level of SWE1 kinase is higher in
cdc55-null cells.
Having determined that decreased
levels of Mih1 phosphatase activity are not the likely cause of Y19
hyperphosphorylation in cdc55-null cells, we then measured
Swe1p levels in wild-type and cdc55
cells. Swe1p levels
normally fluctuate during the cell cycle (31). Therefore, we
compared Swe1p levels in wild-type and cdc55-null cells as
either asynchronous cultures, HU-arrested (S-phase) cells, or
nocodazole-arrested (mitosis) cells (Fig. 4A). In
asynchronous cultures, Swe1p levels in cdc55-null cells were
slightly higher than that seen in wild-type cells. In HU-arrested cells, both strains had similar amounts of Swe1p. However, in nocodazole-arrested cells, while the wild-type strain had barely detectable amounts of Swe1p, cdc55-null cells had a
considerably higher content of Swe1p. The relative levels of Swe1p
found in these two strains, whether as asynchronous cultures or as
nocodazole-arrested cells, correlated surprisingly well with the
relative extent of phosphorylated Cdc28 Y19 found in these two cell
types (35) (data not shown), suggesting that it is
the increased amount of Swe1p in cdc55-null cells that is
the direct cause of Y19 hyperphosphorylation and, consequently, the
abnormal budding morphology.

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 4.
Metaphase-arrested cdc55-null cells contain more
Swe1p than metaphase-arrested wild-type cells. Wild-type and
cdc55-null strains expressing an SWE1 gene tagged
with 12 copies of the MYC epitope were constructed (see Materials and
Methods). Such cells growing in YPD medium at 30°C were collected as
unsynchronized cycling cells (lanes 1 and 2), cells arrested in S phase
with 0.2 M HU for 3 h (lanes 3 and 4), or cells arrested in
mitosis with 20 µg of nocodazole (noc) per ml for 3 h (lanes 5 and 6). Total cell proteins were extracted and analyzed (A) as in Fig.
1, except that we used the monoclonal antibody 9E10 to detect the
MYC-tagged protein. The lower half of the gel not used for the protein
transfer was stained with Coomassie blue to show the relative protein
loading. To see whether the phenomenon of premature sister chromatid
separation exhibited by nocodazole-treated cdc55 cells
was related to increased Swe1p levels, we determined (B) the relative
levels of Swe1p in wild-type (CDC55CDC28),
CDC55CDC28VF, cdc55 CDC28, and
cdc55 CDC28VF strains, each
expressing a MYC-tagged SWE1 gene (see Materials and Methods
for details). Such cells, growing in YPD medium at 30°C, were
collected from asynchronous cultures (cycling) or from cultures that
had been treated with nocodazole (noc) for either 3 or 6 h;
Western analyses were carried out as above. To be able to metaphase
arrest wild-type (CDC55) and cdc55-null cells not
using drug treatment, we created CDC55 and
cdc55 strains expressing
SWE1:MYC12 and also carrying the gene
cdc23-1. The presence of the latter gene allows inactivation
of the APC by raising the temperature of the culture to 35°C.
Cultures of the two strains were grown at 25°C in YPD and
asynchronous early-log-phase cells were collected (lanes 1 and 2),
cultures were treated with HU for 3 h before cell collection
(lanes 5 and 6), or cultures were shifted to 35°C for 3 h before
cell collection (lanes 3 and 4). Total proteins were collected, and
Western blot analyses were carried out to determine Swe1p levels (C).
As another way to determine if the excess Swe1p in the
metaphase-arrested cdc55-null cells was caused by the lethal
effects of the nocodazole or elevated temperature treatments (D), the
same wild-type and cdc55-null cells expressing
SWE1:MYC12 used in panel A were arrested for
3 h with HU and then washed into fresh YPD medium containing no
drug (defined as t = 0). Cells were collected at
intervals following the S-phase release for Western blot analysis and
for microscopically monitoring cell cycle progression as in Fig. 3. In
order to magnify the electrophoretic heterogeneity of the
MYC12-tagged Swe1p, SDS-PAGE was carried out using 6% gels
rather than the standard 10%. Upper panels, percentages of cells in
telophase; middle panels, Swe1p levels; lower panels, loading
controls.
|
|
Although we had shown that nocodazole-treated cdc55
cells
remain arrested in mitosis, this arrest differed from that seen in
wild-type cells, as premature sister chromatid separation occurs in
cdc55-null cells (which, as indicated earlier, we
independently confirmed in our strains [data not shown]). This raised
the question of whether the differences in Swe1p levels we saw were a
consequence of the premature sister chromatid separation. We could
directly address this for the following reason. It was shown
(35) that if in cdc55-null cells the wild-type
CDC28 gene was replaced by CDC28VF
(where threonine 18 is converted to valine and tyrosine 19 to phenylalanine), no premature sister chromatid separation occurs in such
cells when they are nocodazole treated. We therefore measured Swe1p
levels in cells that were either CDC55 CDC28, CDC55
cdc28VF, cdc55
CDC28, or cdc55
CDC28VF, each expressing a chromosomally integrated
SWE1:MYC12 gene. We examined asynchronously
dividing cells and cells that had been treated with nocodazole for 3 or
6 h. As seen in Fig. 4B, nocodazole-treated cdc55-null
cells accumulated much higher levels of Swe1p than controls even when
the CDC28VF gene was present. While the levels
of Swe1p were not as high as in cdc55-null cells carrying a
normal CDC28 gene, this decreased amount of Swe1p was
probably caused by an abolition of the positive feedback of Swe1p on
its own stability, an effect associated with the expression of the
CDC28VF mutant allele (49). In any
event, these results showed that increased Swe1p levels are not caused
by premature sister chromatid separation.
Another way of inducing a metaphase arrest, thereby not relying on
nocodazole treatment and spindle depolymerization, is to inactivate the
APC, thereby inhibiting the proteolysis of proteins normally degraded
during mitosis (19). CDC23 encodes a subunit of
the APC (63). An allele of this gene, cdc23-1,
encodes a protein which, at high temperature, causes the loss of the
ubiquitinating activity of the APC and the subsequent metaphase arrest
of cells carrying this gene (19). We therefore created
wild-type and cdc55-null strains expressing
SWE1:MYC12 and also carrying the cdc23-1 gene. Such cells growing asynchronously at 25°C
showed comparable levels of Swe1p in both strains (Fig. 4C, lanes 1 and 2). Similarly, when these two strains were treated with HU for 3 h, both showed comparable increases in Swe1p levels (Fig. 4C, lanes 5 and 6). However, when CDC55-expressing cells were shifted to
35°C for 3 h, Swe1p levels became undetectable, while in
cdc55
cells a substantial amount of Swe1p remained (Fig.
4C, lanes 3 and 4). In both cases, after 3 h at 35°C, most of
the cells remained large budded with a single nucleus (wild type, 89%;
cdc55
, 90%). These results showed that independent of any
spindle-assembly-related defect, Swe1p levels remained high in
mitotically arrested cdc55
cells.
One potentially trivial reason for the excess Swe1p found in
cdc55-null cells was that the nocodazole-treated cells were
dying (35, 59), thereby inactivating in some unknown way
their protein degradation machinery. Similarly, while
cdc55
cells grow fine at 37°C, the double mutant
cdc55
cdc23-1 is a sick strain, and it is possible that
these cells also die at 35°C. To rule out these potentially trivial
reasons for seeing elevated Swe1p levels in mitotically arrested
cdc55-null cells, we measured the change in levels of Swe1p
in cells that were arrested in S phase with HU and then released from
that arrest. While wild-type cells showed (Fig. 4D) a transient
decrease in Swe1p during G2 and M, cdc55-null cells maintained a more constant level of Swe1p through G2
and M and into the next G1 phase. Furthermore, the
pronounced electrophoretic-mobility changes of Swe1p seen in control
cells, presumably reflecting the hyperphosphorylating activity of Hsl1
kinase (29, 48), were not obvious in cdc55-null
cells. While an initial shift was observed, it was not maintained. As
this Hsl1p-dependent hyperphosphorylation is a normal precursor to
Swe1p destruction in wild-type cells, its apparent absence in
cdc55-null cells is consistent with the maintenance of Swe1p
levels. We concluded that the elevated level of Swe1p in
mitosis-arrested cdc55-null cells was due to the absence of
the decline of this protein that normally occurs during G2 and M phases in wild-type cells and that it was not a biological artifact induced by the nocodazole or high-temperature treatments.
As a way of independently confirming the link between elevated Swe1p
levels in mitosis-arrested cdc55-null cells,
hyperphosphorylation of Cdc28 Y19, and abnormal morphology, we created
the double-knockout strain cdc55
swe1
. As expected, no
Cdc28 Y19 phosphorylation was detected in these cells (data not shown).
More importantly, however, this strain no longer exhibited an abnormal
budding morphology at low temperatures (Fig.
5). This observation strengthens the conclusion that, in cdc55-null cells, it is the elevated
level of Swe1p that is responsible for ectopically inhibiting the Cdc28 kinase activity necessary for proper bud morphogenesis (59).

View larger version (56K):
[in this window]
[in a new window]
|
FIG. 5.
SWE1 expression is essential for the
morphological defect of cdc55-null cells.
cdc55 and swe1 cdc55 strains were grown
on YPD plates at 30°C for 1 day and then shifted to 16°C for 2 more
days. Cells were harvested, washed, fixed, and then microscopically
examined using Nomarski optics. (a) cdc55 cells at
16°C; (b) swe1 cdc55 cells at 16°C.
|
|
An increased Swe1p level in mitosis-arrested cdc55-null
cells is caused mainly by ectopic protein stabilization.
As the
level of Swe1p can be regulated during the cell cycle at the
transcriptional and posttranscriptional phases (36, 50), as
well as the posttranslational level (protein degradation [49]), the increased levels of Swe1p found in
cdc55-null cells could be due to alterations in one or more
of these processes. If the rate of Swe1 transcription were to be
abnormally high and/or the rate of Swe1 mRNA degradation were
ectopically decreased at a particular time during the cell cycle, this
would have caused an excess of Swe1p to be accumulated. In either case,
the manifestation of either of these situations would be an increased
steady-state level of Swe1 mRNA at that time when excess Swe1p was
present in the cell. To see whether this was the case, we performed a Northern blot analysis on RNA extracted from wild-type and
cdc55-null cells that had either been growing asynchronously
or been arrested with HU or nocodazole (a portion of samples which were
also used for Fig. 4A). These data show (Fig.
6) that as previously demonstrated (50), Swe1 mRNA levels are elevated in S-phase-arrested
wild-type cells and considerably depressed in mitosis-arrested cells.
They also show that while Swe1 mRNA levels in S-phase-arrested
wild-type and cdc55-null cells are indistinguishable, the
mRNA level in mitosis-arrested cdc55-null cells is
noticeably elevated relative to that in wild-type controls. Assuming no
differences in the translation efficiencies of Swe1 mRNA in the two
cell types, if the hyperaccumulated Swe1p were only accounted for by
the translation of excess mRNA, the relative excesses of mRNA and
protein levels in cdc55-null cells versus wild-type cells
should be comparable. They are not. In the case of the mRNAs, the
measured ratio (i.e., cdc55-null Swe1 mRNA:wild-type Swe1
mRNA) is about 2.5:1; for Swe1p, the measured ratio (from Fig. 4A) is
almost 11:1. While elevated Swe1 mRNA can account for some of the
excess Swe1p present in cdc55-null cells, it clearly can
account for only a small part of it. From these data we cannot tell
whether the excess Swe1 mRNA in mitosis-arrested cdc55-null
cells is the result of increased Swe1 transcription, a decrease in rate
of Swe1 mRNA degradation, or both.

View larger version (75K):
[in this window]
[in a new window]
|
FIG. 6.
Swe1 mRNA levels in S- and M-phase-arrested wild-type
and cdc55-null cells. Total RNA was extracted from cells
that were treated in the same manner as those shown in Fig. 4A. The
RNAs were separated on 1% agarose gels and transferred to filters for
Northern blot analysis (upper panel). The probe for Swe1 mRNA was
generated by random primer labeling a 0.6-kb
HindIII/XbaI fragment from the
SWE1 ORF. As an indication of relative lane loading, the
lower panel shows the ethidium bromide-stained gel prior to transfer.
Lanes 1, 3, and 5: wild-type cells as cycling, HU-arrested, and
nocodazole-arrested samples, respectively; lanes 2, 4, and 6:
cdc55 cells as cycling, HU-arrested, and
nocodazole-arrested samples, respectively.
|
|
While Swe1p is relatively stable during S phase and early
G2, its degradation rate increases some four- to fivefold
sometime early in G2 (49). This increased
degradation rate continues on into mitosis. Thus, one way that Swe1p
levels could be elevated in nocodazole-arrested cdc55-null
cells would be if this normal increase in rate of Swe1p degradation
were somehow prevented. We examined this possibility in the following
way. Wild-type and cdc55-null strains were constructed in
which the SWE1 gene was replaced by a MYC-tagged
SWE1 gene driven by a GAL1 promoter. Such cells,
while in log-phase growth in raffinose-containing medium, were
nocodazole arrested. Swe1 transcription was transiently induced in the
arrested cells by adding galactose to 2% for 0.5 h and then
transferring them into glucose medium. Throughout this time, nocodazole
was maintained in the culture medium to keep cells in mitotic arrest.
We initially monitored Swe1 mRNA levels in these cells and found (Fig.
7a) that following the final shift into
glucose medium, in both wild-type and cdc55-null cells the levels of Swe1 mRNA rapidly decreased, as expected, being barely detectable at 50 min and undetectable at 90 min. Thus, 50 min following
the shutoff of the SWE1 gene, the cellular level of Swe1p in
each of these cells would essentially be determined solely by the
degradation rate of Swe1p. Accordingly, we repeated the above
experimental protocol, only this time we monitored the levels of Swe1p
in the two cell types beginning 50 min after Swe1 transcription was
terminated. As seen in Fig. 7b, Swe1p levels remained high for several
hours in cdc55-null cells while they significantly declined
in wild-type cells. Quantitation of these data (Fig. 7c) indicated that
while Swe1p turned over with a half-life of approximately 40 min, the
Swe1p half-life in cdc55-null cells was >200 min. Thus, it
is most likely that this difference in Swe1p degradation rate is the
major cause of the excess Swe1p found in nocodazole-arrested
cdc55-null cells.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 7.
Normal Swe1p degradation is suppressed in
mitosis-arrested cdc55-null cells. To determine the relative
rates of degradation of Swe1 mRNA in wild-type and cdc55-null cells,
strains expressing chromosomally integrated
SWE1-MYC12 genes driven by a GAL1
promoter (see Materials and Methods) were developed. Such cells were
grown in YP raffinose to early log phase and then arrested in
nocodazole (20 µg/ml) for 3 h. The arrest phenotype was
confirmed by microscopic analysis. Galactose was added to each culture
to 2% for 30 min to transiently induce SWE1 transcription.
Cells were then collected by centrifugation, washed, and resuspended in
YPD medium containing nocodazole in order to suppress any further Swe1
mRNA production and to maintain mitotic arrest. Cells were harvested at
0, 25, 50, and 90 min after repression of transcription. Total RNA was
extracted, and a Northern analysis (as in Fig. 5) was carried out (a,
upper panel). The ethidium bromide-stained agarose gel prior to
transfer served as a loading control (a, lower panel). Based on the
above results, we measured Swe1p degradation in the following way. Swe1
mRNA was transiently induced as above. Beginning at 50 min after the
SWE1 expression had been suppressed by glucose (defined as
t = 0), cells were collected at intervals and the
levels of Swe1p were determined (b) as in Fig. 3. Western blots were
scanned and quantitated, the levels of Swe1p were plotted (c), and the
degradation rates of Swe1p in wild-type and cdc55 cells
were calculated.
|
|
Unregulated PP2A activity is the cause of excess Swe1p
accumulation.
The absence of Cdc55p, the B-regulatory subunit of
the trimeric PP2A, could alter PP2A activity in one of three ways. It
could cause the loss of a particular phosphatase activity, it could result in the excessive increase of an already present activity, or it
could elicit a novel, i.e., not normally present, phosphatase activity.
If the abnormal morphology of cdc55-null cells at low temperature is caused by a loss of a particular PP2A phosphatase activity, one might have expected that the loss of one or both of the
PP2A catalytic subunit genes (PPH21 and PPH22)
would induce budding defects similar to those exhibited by
cdc55-null cells. However, this is not the case
(40). On the other hand, if loss of Cdc55p elicits a gain of
PP2A function, either a novel one or one already present in the cell,
removing one or both of the PP2A catalytic subunit genes in a
cdc55-null strain might suppress the morphological defect.
Accordingly, we constructed cdc55
pph21
, cdc55
pph22
, and cdc55
pph21
pph22
strains and observed their growth properties and morphologies at
16°C. While the two double-disruption strains had the same growth
properties and morphologies as cdc55-null cells, the
triple-knockout strain, while still showing a few cells with abnormal
buds at 16°C, was essentially cured of the
cdc55
-induced morphological phenotype (Fig.
8). These cells did grow more slowly at
all temperatures when compared with cdc55-null cells, but no more slowly than pph21
pph22
cells, and their
morphologies were also indistinguishable from pph21
pph22
cells (data not shown).

View larger version (67K):
[in this window]
[in a new window]
|
FIG. 8.
Disrupting both PPH21 and PPH22 in
cdc55-null cells suppresses the morphological defect.
Wild-type, cdc55 , pph21 cdc55 ,
pph22 cdc55 , and pph21 pph22 cdc55
strains were grown on YPD plates at 30°C for 1 day and then were
shifted to 16°C for 2 days. Cells were harvested, washed, fixed, and
then microscopically examined using Nomarski optics. (a) Wild-type
cells; (b) cdc55 cells; (c) pph21 cdc55
cells; (d) pph22 cdc55 cells; (e) pph21
pph22 cdc55 cells.
|
|
While the above data were consistent with a
gain-of-phosphatase-function phenotype for cdc55-null cells,
because the loss of both PP2A catalytic subunit genes disrupts the
normal actin cytoskeleton (28) and produces somewhat swollen
cells as a result of its abnormal cell wall (14), it was
possible that the suppression of the abnormal budding phenotype in the
triple-disruption strain was indirectly masked by the phenotype induced
by the absence of Pph21p and Pph22p. To address the question of whether
the removal of Pph21p and Pph22p from cdc55-null cells had a
more direct effect on suppressing the abnormal budding morphology, we
asked whether Pph21p and Pph22p activity could be shown to be
responsible for elevated levels of Swe1p. To do this, we constructed a
strain in which the three genes, CDC55, PPH21,
and PPH22, were all disrupted and which contained a
chromosomally integrated, MYC-tagged SWE1 gene. Such cells,
as well as the wild-type and cdc55
strains expressing the
MYC-tagged SWE1 gene, were grown at 30°C and then arrested
in mitosis with nocodazole. Proteins from these cells were isolated,
and the levels of Swe1p were determined in each by Western blot
analysis (Fig. 9). As seen earlier (Fig.
4A), nocodazole-arrested cdc55-null cells contain
considerably more Swe1p than wild-type cells. However, the Swe1p
content of the triple-disruption strain was reduced to almost the level
of that seen in wild-type cells. Taken together, these results show
that it is the abnormally regulated catalytic activity of Pph21p and Pph22p in cdc55-null cells that is responsible for the
elevated levels of Swe1p and, ultimately, the abnormal budding
morphology of these cells. What the target(s) of this activity is
remains to be determined.

View larger version (66K):
[in this window]
[in a new window]
|
FIG. 9.
Disrupting PPH21 and PPH22 in a
cdc55-null strain lowers Swe1p levels in metaphase-arrested
cells. Wild-type, cdc55 and pph21 pph22
cdc55 cells (all expressing MYC-tagged SWE1 genes)
were grown at 30°C in YPD medium to early log phase. Wild-type and
cdc55-null cells were arrested with nocodazole (20 µg/ml) for 3 h. pph21 pph22 cdc55 cells ( 21 22 55) were
treated with nocodazole for 5 h because of the slow growth rate of
these cells. The arrest phenotype of all cells was microscopically
confirmed prior to their harvest. Western analyses of the proteins
isolated from these cells were carried out using anti-MYC antibody to
measure Swe1p levels (upper panel) and anti-PSTAIR antibody to detect
Cdc28p and Pho85p in order to determine relative protein loading in
each lane (lower panel). Lane 1, wild-type cells; lane 2, cdc55 cells; lane 3, pph21 pph22
cdc55 cells.
|
|
 |
DISCUSSION |
Given that the budding defect in cdc55-null cells is
elicited by the hyperphosphorylation of Cdc28p Y19 and the resulting increased inhibition of this kinase, our results show that this excess
phosphorylation is due in large part, if not exclusively, to the
ectopic accumulation of Swe1p in these cells. We have shown that
elevated Swe1p levels occur because the increased rate of turnover of
Swe1p that is normally induced during G2 in wild-type cells
does not occur in cdc55-null cells. These elevated levels of
Swe1p in cdc55-null cells apparently maintain continued
inhibition of Cdc28 kinase activity at a time when, in wild-type cells,
Cdc28 kinase is normally required to regulate the shift from axial to isotropic bud growth (26). Without that switch, abnormal bud development and, hence, the mutant phenotype, can occur.
We believe that while the increased level of Cdc28 Y19 phosphorylation
seen in cdc55-null cells is important in inhibiting Cdc28
kinase activity, the increased Swe1p levels themselves can contribute
to this inhibition. Swe1p has been shown to be able to inhibit Cdc28p
activity through a mechanism independent of Swe1 kinase activity
(30). Consistent with this, we found that when Swe1p was
overproduced to a level at least 10 times higher than its normal
endogenous level, thereby causing a G2/M arrest, the
phosphorylation level on Y19 of Cdc28 in such cells was no higher than
that of wild-type controls (data not shown). Furthermore, under these
conditions, we found that Cdc28p could be coimmunoprecipitated with
Swe1p (data not shown). Thus, Swe1p may bind to Cdc28p and inhibit its
activity without increasing the extent of Y19 phosphorylation. In
addition, mih1-null cells have a much higher Y19
phosphorylation level than do cdc55-null cells during
mitosis (Fig. 2), yet mih1-null cells show only a mildly
elongated morphology without a failure of cytokinesis, thus indicating
that a high level of Y19 phosphorylation is not sufficient to elicit a
cdc55-null-like phenotype. If in cdc55-null cells
the abnormal morphology were caused solely by the increased Y19
phosphorylation, then when this phosphorylation level was further
increased in a cdc55
mih1
strain, such cells should
show an even more abnormal morphology, but that is not what we found
(data not shown). The double-null cells appear just like
cdc55-null cells, with relatively normal morphology at
30°C and a similar cdc55-null morphology at 16°C (data
not shown). We conclude that increasing the Swe1p abundance in
cdc55-null cells down-regulates Cdc28 kinase activity, by
both Swe1 kinase-dependent and -independent mechanisms.